Fate stock: buy or sell?
December 6th, 2019
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Should I buy Fate stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Fate Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Fate Therapeutics stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we gathered 14 ratings published for FATE stock in the last 30 days. The general sentiment of these ratings is bullish for FATE stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-16||Piper Jaffray Companies||n/a||Overweight|
|2019-6-27||Piper Jaffray Companies||Overweight||Top Pick|
|2019-3-6||Wells Fargo & Co||n/a||Outperform|
Fate stock analysis
Fate shares raised 0.74% to $13.67 today.
Shares of Fate ended today at $13.67 and raised a slightly fine 0.74%. Since price and SMA200d lines crossed down on September, FATE fell $-4.53 per share (-24.89%).
After boosting a super good 7.87% in a week last week, Fate Therapeutics closed this week at $13.67 and collapsed a hair-raising -12.48%.
Since price and 40-weeks moving average lines crossed down late September, FATE fell $-4.53 per share (-24.89%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Far behind is the all-time high Fate recorded by mid July and since then the price is -40.10% below that top.
Fate stock price history
Fate IPO was on October 1st, 2013 at $6.56 per share1. Since then, FATE stock surged a 108.40%, with an average of 18.10% per year. If you had invested right after FATE's IPO a $1,000 in Fate stock in 2013, it would worth $1,084.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Fate stock historical price chart
FATE stock reached all-time highs on July with a price of $22.82.
Fate stock price target is $25.80How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' FATE stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 13 price predictions for Fate stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-16||Piper Jaffray Companies||Lowers Target||$30.00||$28.00||-6.7%|
|2019-6-27||Piper Jaffray Companies||Reiterates||$23.00||$30.00||30.4%|
|2019-3-6||Wells Fargo & Co||Reiterates||$18.00||$24.00||33.3%|
Financials and fundamental analysis
Earnings date and Earnings per ShareFate reported tiny results for 2018-Q4 on March. Fate stepped up Earnings per Share (EPS) by 4.20%, beating analysts consensus of $-0.24. Fate posted $-0.25.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Fate Therapeutics annual revenues rocketed an exceptional 15.44% to $4.74 million USD from $4.11 marked in 2017. When comparing 2018 vs 2017, in contrast, profit margin (that is, the net income divided by revenues) plunged a -358.94% to -1,405.02%.
|2013||$0.97 M||-||$-20.89 M-2151.4%||-|
|2015||$2.43 M||150.36%||$-29.99 M-1233.7%||43.57%|
|2016||$4.40 M||81.08%||$-33.46 M-760.2%||11.57%|
|2017||$4.11 M||-6.72%||$-42.95 M-1046.1%||28.36%|
|2018||$4.74 M||15.44%||$-66.60 M-1405.0%||55.05%|
Quarterly financial resultsFate Therapeutics reported $1.66 M in sales for 2018-Q4, a 61.89% up compared to previous quarter. Reported quarter earnings marked $-16.03 M with a profit margin of -964.90%. Profit margin skyrocketed a 670.77% compared to previous quarter when profit margin was -1,635.67%. When comparing turnover to same quarter last year, Fate sales marked an astounding growth and climbed a 61.73%.
|2017-Q1||$1.03 M||-||$-10.13 M-983.5%||-|
|2017-Q2||$1.03 M||0.00%||$-9.65 M-936.9%||-4.74%|
|2017-Q3||$1.03 M||0.00%||$-10.68 M-1036.9%||10.67%|
|2017-Q4||$1.03 M||-0.29%||$-12.50 M-1216.8%||17.01%|
|2018-Q1||$1.03 M||-0.10%||$-14.14 M-1377.7%||13.11%|
|2018-Q2||$1.03 M||0.10%||$-19.65 M-1913.7%||39.04%|
|2018-Q3||$1.03 M||-0.10%||$-16.78 M-1635.7%||-14.61%|
|2018-Q4||$1.66 M||61.89%||$-16.03 M-964.9%||-4.50%|
Fate ownershipWhen you are planning to buy a company, it's worth to review its ownership structure.
Fate shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.29% of all shares.
Bearish positions for FATE stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Fate:
|Market cap||$1.0 B||$70.4 B||$9.1 B||$10.8 B||$3.0 B|
|Total shares||75.6 M||270.0 M||140.7 M||92.1 M||61.6 M|
|Float shares||63.3 M||269.9 M||128.0 M||90.8 M||56.3 M|
|- Institutional holdings (%)||96.7%||87.5%||85.9%||105.1%||85.6%|
|- Insider holdings (%)||2.3%||0.3%||9.1%||1.3%||2.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$13.26 - $13.92|
|Average true range||$0.73|
|50d mov avg||$14.63|
|100d mov avg||$16.72|
|200d mov avg||$17.42|
Fate performanceTo better understand Fate Therapeutics performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Fate Therapeutics against Becton, Dickinson and, Ionis Pharmaceuticals, Neurocrine Biosciences, PTC Therapeutics and Sarepta Therapeutics in the following table: